Report Content
Chapter 1 Methodology & Scope
1.1 Industry coverage
1.2 Market scope & definitions
1.3 Base estimates & working
1.3.1 Data collection
1.4 Forecast parameters
1.5 COVID-19 impact at global level
1.6 Data validation
1.7 Data sources
1.7.1 Primary
1.7.2 Secondary
1.7.2.1 Paid sources
1.7.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Prostate cancer diagnostics industry 360º synopsis, 2018 – 2032
2.2 Business trends
2.3 Regional trends
2.4 Test type trends
2.5 Cancer type trends
2.6 End-use trends
Chapter 3 Prostate Cancer Diagnostics Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of prostate cancer
3.2.1.2 Technological advancements
3.2.1.3 Surging awareness and screening initiatives
3.2.1.4 Increasing popularity of prostate cancer diagnostic tests
3.2.2 Industry pitfalls & challenges
3.2.2.1 Lack of skilled professionals
3.2.2.2 Stringent regulations
3.3 Growth potential analysis
3.3.1 By test type
3.3.2 By cancer type
3.3.3 By end-use
3.4 COVID-19 impact analysis
3.5 Regulatory landscape
3.5.1 U.S.
3.5.2 Europe
3.6 Reimbursement scenario
3.7 Pricing analysis, 2022
3.8 Technology landscape
3.9 Future market trends
3.10 Gap analysis
3.11 Porter’s analysis
3.12 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis, 2022
4.4 Competitive positioning matrix
4.5 Vendor matrix analysis
4.6 Strategy dashboard, 2022
Chapter 5 Prostate Cancer Diagnostics Market Size and Forecast, By Test Type (USD Million & Units)
5.1 Key test type trends
5.2 Imaging Tests
5.3 Biomarker Tests
5.4 Biopsy
5.5 Immunohistochemistry
5.6 Others
Chapter 6 Prostate Cancer Diagnostics Market Size and Forecast, By Cancer Type (USD Million)
6.1 Key cancer type trends
6.2 Benign prostatic hyperplasia
6.3 Prostatic adenocarcinoma
6.4 Small cell carcinoma
6.5 Others
Chapter 7 Prostate Cancer Diagnostics Market Size and Forecast, By End-use (USD Million)
7.1 Key end-use trends
7.2 Hospitals
7.3 Diagnostic Laboratories
7.4 Cancer Research Institutes
7.5 Others
Chapter 8 Prostate Cancer Diagnostics Market Size and Forecast, By Region (USD Million & Units)
8.1 Key regional trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Poland
8.3.7 Sweden
8.3.8 The Netherlands
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Indonesia
8.4.7 Philippines
8.4.8 Vietnam
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Argentina
8.5.4 Columbia
8.5.5 Chile
8.5.6 Peru
8.6 Middle East & Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Turkey
8.6.5 Iran
8.6.6 Israel
Chapter 9 Company Profiles
9.1 Abbott Laboratories
9.2 Agilent Technologies
9.3 AstraZeneca Plc.
9.4 Bayer
9.5 Becton Dickinson and Company
9.6 Biocept Inc.
9.7 Danaher Corporation
9.8 F. Hoffmann-La Roche AG
9.9 Foundation Medicine Inc.
9.10 Genomic Health Inc.
9.11 Genomic Health.
9.12 Hologic, Inc.
9.13 MDxHealth SA
9.14 Myriad Genetics Inc.
9.15 OPKO Health, Inc.
9.16 Siemens Healthineers AG
9.17 Vyant Bio Inc.
